Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation

Inclusion Criteria * Male and female patients aged 18 years or more * CF and non-CF patients receiving single-lung or double-lung or heart-lung transplantation for the first time * Patients on oral tacrolimus and MMF for at least 48 hours at the time of inclusion (administration via a naso-gastric tube possible if necessary) * Patients without progressive chronic pathology jeopardizing short term patient and graft survival * Patients accepting to comply with at least the evaluation visits planned in the investigation center over the first three years post-transplantation (D7, D14, M1, M3, M6, M12, M18, M24, M30, M36) * Patients giving their free and informed written consent to participate in this study * Patients with a health insurance policy or registered under a health insurance program Exclusion Criteria: * Patients aged less than 18 years or patients over 18 years under guardianship * Patients who disagree with this research * Patients with a contra-indication to receiving tacrolimus or MMF * Patients on cyclosporine, sirolimus or everolimus * Patients who have already benefited from a solid organ transplantation in the past (including lung or heart-lung transplantation) * Patients infected by Burkholderia cenocepacia (Burkholderia cepacia genomovar III) * Patients receiving HIV protease inhibitors (major pharmacokinetic interaction with tacrolimus) * Pregnant or breastfeeding women or those of child-bearing age who do not use an efficient contraceptive method * Drug users or patients suffering from neuro-psychiatric disorders preventing them from both proper comprehension of the protocol and reliable consent * Patients already participating in another interventional clinical trial